華訊(00833.HK)預計年度將錄得重大虧損超過2億港元
格隆匯3月18日丨華訊(00833.HK)公佈,此前董事會已指出公司仍在評估債項的預期減值虧損,債項如須要作出全數減值虧損,集團截至2019年12月31日止年度的全年業績有可能錄得重大虧損。基於之後與買方及擔保人之商議及迄今就收回債項作出的努力,公司認為於可見將來收回債項全數的可能性不大。
此外,近期爆發之新冠狀病毒肺炎亦可能對擔保人根據買賣協議須履行其償還債項責任之能力造成非常重大不利影響。因此,董事會認為,於集團截至2019年12月31日止年度的全年業績內須要為債項作出全數減值虧損,惟須待公司之核數師同意後,方可作實。因此,集團截至2019年12月31日止年度的全年業績將會錄得超過2億港元的重大虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.